SecBot SecBot
PRESS-RELEASE ·Filed Mar 19, 2026

CMMB

Chemomab Therapeutics Ltd.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The FDA's agreement on a streamlined path to approval based on a single Phase 3 trial significantly de-risks the development pathway for nebokitug. Traders should monitor upcoming Phase 3 initiation, partnership developments, and clinical event accrual. The strong biomarker data and regulatory designations (Orphan Drug, Fast Track) increase the likelihood of commercial success if Phase 3 confirms clinical benefit.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.93
T+0 close · Mar 19, 2026 · via day close
Latest settled
−18.13%
T+60 · $1.58
Vs SPY
−32.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $1.93entry
  2. T+1 · 8mo ago −7.77%α −6.03% · $1.78
  3. T+5 · 8mo ago −19.69%α −17.48% · $1.55
  4. T+20 · 7mo ago −13.47%α −21.09% · $1.67
  5. T+60 · 5mo ago −18.13%α −32.48% · $1.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab Therapeutics reported its full-year and Q4 2025 financial results, highlighted by a successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), alignment on a single Phase 3 trial for potential approval, and strong clinical data presentations. The company has $10.4M in cash, sufficient to fund operations into Q1 2027, while R&D expenses declined due to completion of its Phase 2 trial.

Key Financial Metrics

EPS
$-0.02

Key Facts

  • FDA aligned with Chemomab on a single Phase 3 trial as a potential path to full approval for nebokitug in PSC, with a clinical event-driven primary endpoint.
  • Phase 2 SPRING trial data published in peer-reviewed journals and presented at major liver disease conferences, including AASLD and DDW, with multiple 'posters of distinction' and a Best Oral Presentation award.
  • Cash position was $10.4 million as of December 31, 2025, down from $14.3 million in 2024, but provides runway into Q1 2027.
  • R&D expenses decreased to $5.8M in 2025 from $11.3M in 2024 due to completion of the Phase 2 trial.
  • Net loss narrowed to $9.0M in 2025 from $13.9M in 2024.
  • Shares outstanding increased to 575.4M from 377.1M due to financing activities, reflecting a reverse ADS split from 1:20 to 1:80 effective August 2025.

Financial Impact

Reduced R&D spend by $5.5M YoY and narrowed net loss by $4.9M, while maintaining sufficient cash runway into 2027 despite lower cash balance.

cashr_d_expensenet_lossshares_outstanding

Risk Factors

  • High reliance on a single asset (nebokitug) and indication (PSC), with no approved products yet.
  • Future financing needs likely beyond Q1 2027, which could lead to dilution.
  • Forward-looking statements highlight risks around FDA approval, clinical trial execution, manufacturing, and geopolitical exposure in Israel.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258911

US Market Status

Market Closed · Opens in 9h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026